Aytu Biopharma (AYTU) Cash from Financing Activities (2010 - 2026)
Aytu Biopharma (AYTU) posted quarterly Cash from Financing Activities of $872000.0 for Q1 2026, down 79.72% year-over-year from $4.3 million in Q1 2025, and up 113.92% quarter-over-quarter from -$6.3 million in Q4 2025.
Aytu Biopharma (AYTU) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Aytu Biopharma (AYTU) has reported Cash from Financing Activities for 17 consecutive years, with $872000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 79.72% year-over-year to $872000.0; the TTM figure through Mar 2026 stood at $9.9 million (up 181.35% YoY), while the FY2025 annual figure was $15.4 million, up 1323.69% from the prior year.
- Cash from Financing Activities improved to $872000.0 in Q1 2026 per AYTU's latest filing, from -$6.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $13.6 million in Q3 2022 and bottomed at -$6.3 million in Q4 2025.
- Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $872000.0 in 2026.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 2090.48% — and 2025, when it surged 1116.57%.
- Aytu Biopharma's Cash from Financing Activities stood at -$1.9 million in 2022, then jumped by 93.24% to -$126000.0 in 2023, then slumped by 2090.48% to -$2.8 million in 2024, then sank by 126.92% to -$6.3 million in 2025, then soared by 113.92% to $872000.0 in 2026.
- Business Quant data shows AYTU's Cash from Financing Activities at $872000.0 in Q1 2026, -$6.3 million in Q4 2025, and $2.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Aytu Biopharma | 24.49 Mn | -2.22 Mn | 7.60 Mn | 872,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 872,000.00 |
| Mar 31, 2026 | 872,000.00 |
| Dec 31, 2025 | -6.26 Mn |
| Dec 31, 2025 | -6.26 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Sep 30, 2025 | 2.30 Mn |
| Jun 30, 2025 | 12.99 Mn |
| Jun 30, 2025 | 12.99 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Dec 31, 2024 | -2.76 Mn |
| Sep 30, 2024 | 911,000.00 |
| Sep 30, 2024 | 911,000.00 |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 530,000.00 |
| Mar 31, 2024 | 530,000.00 |
| Dec 31, 2023 | -126,000.00 |
| Dec 31, 2023 | -126,000.00 |